Man Who Predicted March 2020 Crash Says 2021 Is The Time
If you've got money invested in the stock market, but are confused as to what to do next...This is the can't-miss interview of 2021...
Learn more here!

GRTX Insider Trading (Galera Therapeutics)

Insider Ownership Percentage: 19.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $19,189,562.40

Galera Therapeutics Insider Trading History Chart

Galera Therapeutics Share Price & Price History

$8.06
▼ -0.2 (-2.42%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

Galera Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/18/2021Holdings A/S NovoMajor ShareholderSell500,000$10.58$5,290,000.002,459,021  
11/13/2020Joel F SussmanCAOSell10,000$10.32$103,200.0010,000  
10/26/2020Jon T HolmlundInsiderSell2,244$15.00$33,660.002,244  
10/15/2020Holdings A/S NovoMajor ShareholderSell450,000$11.00$4,950,000.002,959,021  
10/5/2020Jon T HolmlundInsiderSell100$12.00$1,200.00100  
6/19/2020Bioventures Ltd NovartisMajor ShareholderSell1,001,312$8.25$8,260,824.00  
6/17/2020Bioventures Ltd NovartisMajor ShareholderSell4,622$9.27$42,845.94  
6/15/2020Bioventures Ltd NovartisMajor ShareholderSell6,164$9.05$55,784.20  
6/12/2020Bioventures Ltd NovartisMajor ShareholderSell17,232$8.72$150,263.04  
6/10/2020Bioventures Ltd NovartisMajor ShareholderSell8,532$9.46$80,712.72  
6/8/2020Bioventures Ltd NovartisMajor ShareholderSell5,659$9.66$54,665.94  
6/4/2020Bioventures Ltd NovartisMajor ShareholderSell4,088$9.55$39,040.40  
6/2/2020Bioventures Ltd NovartisMajor ShareholderSell5,669$9.68$54,875.92  
5/26/2020Jon T HolmlundInsiderSell692$12.00$8,304.00692  
5/11/2020Jon T HolmlundInsiderSell185$12.00$2,220.005,102  
5/7/2020Jon T HolmlundInsiderSell2,059$12.00$24,708.003,064  
5/5/2020Jon T HolmlundInsiderSell3,064$12.16$37,258.243,064  
11/12/2019Enterprise Associates 14 NewMajor ShareholderBuy416,666$11.79$4,912,492.14
11/12/2019Holdings A/S NovoInsiderBuy500,000$12.76$6,380,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Galera Therapeutics (NASDAQ:GRTX)

75.41% of Galera Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Galera Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/25/2021Hsbc Holdings PLC13,274$0.14M0.0%N/A0.053%
2/19/2021JPMorgan Chase & Co.22,564$0.23M0.0%+262.1%0.090%
2/16/2021Squarepoint Ops LLC12,428$0.13M0.0%N/A0.050%
2/12/2021Caas Capital Management LP178,141$1.82M0.0%N/A0.714%
2/11/2021Northern Trust Corp98,763$1.01M0.0%-5.0%0.396%
2/11/2021Frazier Management LLC241,000$2.47M0.2%N/A0.966%
2/10/2021Renaissance Technologies LLC20,770$0.21M0.0%+58.9%0.083%
2/10/2021Panagora Asset Management Inc.33,731$0.35M0.0%+4,795.6%0.135%
2/9/2021Wells Fargo & Company MN34,611$0.35M0.0%+407.9%0.139%
2/9/2021Bank of New York Mellon Corp34,273$0.35M0.0%+42.0%0.137%
2/8/2021New York State Common Retirement Fund8,800$90K0.0%+1,000.0%0.035%
2/5/2021BlackRock Inc.536,965$5.49M0.0%+27.1%2.152%
2/4/2021State of Wisconsin Investment Board12,300$0.13M0.0%N/A0.049%
2/2/2021Taylor Wealth Management Partners64,753$0.66M0.3%+4.2%0.260%
11/17/2020VR Adviser LLC51,653$0.47M0.1%N/A0.207%
11/13/2020Morgan Stanley2,777$25K0.0%-52.1%0.011%
11/10/2020State Street Corp82,772$0.75M0.0%-3.1%0.333%
11/6/2020BlackRock Inc.422,640$3.82M0.0%+6.4%1.699%
10/14/2020Taylor Wealth Management Partners62,171$0.56M0.3%+3.7%0.250%
8/25/2020Nuveen Asset Management LLC14,027$100K0.0%N/A0.056%
8/20/2020Charles Schwab Investment Management Inc.18,833$0.14M0.0%N/A0.076%
8/17/2020Jacobs Levy Equity Management Inc.36,161$0.26M0.0%N/A0.145%
8/14/2020Bank of America Corp DE9,737$69K0.0%+206.0%0.039%
8/13/2020Tekla Capital Management LLC1,041,845$7.44M0.3%+150.0%4.197%
8/12/2020American International Group Inc.5,348$38K0.0%+427.9%0.022%
8/12/2020Bank of New York Mellon Corp24,131$0.17M0.0%+108.1%0.097%
7/27/2020Taylor Wealth Management Partners59,930$0.43M0.2%N/A0.241%
7/20/2020TCI Wealth Advisors Inc.5,962$43K0.0%N/A0.024%
7/17/2020Raymond James Financial Services Advisors Inc.28,561$0.20M0.0%N/A0.115%
6/19/2020State Street Corp15,084$0.14M0.0%N/A0.061%
5/15/2020RA Capital Management L.P.893,115$8.49M0.3%-15.3%3.598%
5/15/2020Squarepoint Ops LLC12,670$0.12M0.0%N/A0.051%
5/15/2020Weiss Multi Strategy Advisers LLC48,492$0.46M0.0%-19.2%0.195%
5/15/2020Morgan Stanley4,747$45K0.0%+101.5%0.019%
5/14/2020Wells Fargo & Company MN5,285$50K0.0%+3,757.7%0.021%
5/14/2020Geode Capital Management LLC49,217$0.47M0.0%+31.7%0.198%
5/14/2020Sphera Funds Management LTD.475,677$4.52M0.6%+0.9%1.917%
5/11/2020Ensign Peak Advisors Inc8,925$85K0.0%-64.3%0.036%
5/11/2020State Street Corp15,084$0.14M0.0%N/A0.061%
5/6/2020Bank of New York Mellon Corp11,596$0.11M0.0%N/A0.047%
5/1/2020BlackRock Inc.71,557$0.68M0.0%+5.8%0.288%
3/3/2020Norges Bank26,900$0.35M0.0%N/A0.108%
2/20/2020Geode Capital Management LLC37,374$0.49M0.0%N/A0.151%
2/19/2020Perceptive Advisors LLC325,000$4.28M0.1%N/A1.310%
2/14/2020Perceptive Advisors LLC325,000$4.28M0.1%N/A1.310%
2/14/2020RA Capital Management L.P.1,054,178$13.87M0.4%N/A4.249%
2/14/2020Blackstone Group Inc1,678,984$22.10M0.1%N/A6.768%
2/14/2020UBS Group AG3,389$45K0.0%N/A0.014%
2/14/2020Sofinnova Investments Inc.3,083,712$40.58M2.9%N/A12.430%
2/7/2020Tower Research Capital LLC TRC2,120$28K0.0%N/A0.009%
Data available starting January 2016

See Full Table
Galera Therapeutics logo
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $8.06
$7.91
$8.50

50 Day Range

MA: $10.48
$8.23
$11.83

52 Week Range

Now: $8.06
$6.58
$15.00

Volume

88,838 shs

Average Volume

66,521 shs

Market Capitalization

$201.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Who are the company insiders with the largest holdings of Galera Therapeutics?

Galera Therapeutics' top insider investors include:
  1. Holdings A/S Novo (Major Shareholder)
  2. Joel F Sussman (CAO)
  3. Jon T Holmlund (Insider)
  4. Bioventures Ltd Novartis (Major Shareholder)
  5. Enterprise Associates 14 New (Major Shareholder)
  6. Holdings A/S Novo (Insider)
L.O.C.K. System Predicts Crash Before April
Joel Litman’s L.O.C.K. system has a history of spotting winners and losers – long before the mainstream media. Like when it spotted the March 2020 crash – a month early. Now it says a massive market shift could be coming – as soon as April. And most Americans are woefully unprepared.
Click Here Now!
pixel